Belzutifan is usually a CYP2C19 substrate. Coadministration with CYP2C19 inhibitors could improve incidence or severity of adverse effects. Observe for anemia and hypoxia and lower belzutifan dose as recommended.Keep away from or substitute A different drug for these medications when achievable. Evaluate for lack of therapeutic outcome if medicatio